Article
Clinical Neurology
M. A. Lobo Chaves, Matthew Gittins, Benjamin Bray, Andy Vail, Craig J. Smith
Summary: This study described the variation of observed stroke-associated pneumonia in England and Wales among stroke patients, finding that patient baseline characteristics only accounted for 5% of the observed variation. Additional explanations for the observed variation in stroke-associated pneumonia need to be explored to reduce variation in antibiotic use for stroke patients.
INTERNATIONAL JOURNAL OF STROKE
(2022)
Review
Biochemistry & Molecular Biology
Eun Chae Lee, Tae Won Ha, Dong-Hun Lee, Dong-Yong Hong, Sang-Won Park, Ji Young Lee, Man Ryul Lee, Jae Sang Oh
Summary: Stroke is a leading cause of death and neurological disorders globally, but diagnostic techniques and treatments are limited for certain types. Recent studies have focused on the clinical value of utilizing exosome mechanisms and reported changes in diagnostic biomarkers of exosomes after stroke, as well as their potential applications in therapeutics.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Infectious Diseases
Aline Wolfensberger, Lauren Clack, Stefanie von Felten, Mirjam Faes Hesse, Dirk Saleschus, Marie-Theres Meier, Katharina Kusejko, Roger Kouyos, Leonhard Held, Hugo Sax
Summary: This study aimed to test a prevention intervention for non-ventilator-associated hospital-acquired pneumonia and a multifaceted implementation strategy. The results showed that implementing the prevention intervention significantly reduced the incidence rate of nvHAP.
LANCET INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Maria Bouam, Christine Binquet, Florian Moretto, Thibault Sixt, Michele Vourc'h, Lionel Piroth, Patrick Ray, Mathieu Blot
Summary: This study aimed to investigate whether a delayed diagnosis of community-acquired pneumonia (CAP) in the emergency department (ED) is associated with worse outcome. The results showed that a delayed diagnosis was associated with a less severe clinical presentation, the absence of obvious signs of pneumonia on chest X-ray, and delayed antibiotic initiation, but was not associated with in-hospital mortality.
FRONTIERS IN MEDICINE
(2023)
Article
Geriatrics & Gerontology
Elzbieta Gradek-Kwinta, Agnieszka Slowik, Tomasz Dziedzic
Summary: The study found that the use of anticholinergic medication before stroke is associated with an increased risk of stroke-associated pneumonia (SAP), suggesting that the use of anticholinergic medication may increase the risk of pneumonia after a stroke.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2022)
Article
Immunology
Guomei Shi, Wenxiu Chen, Pengyu Gong, Meng Wang, Junshan Zhou, Xiaorong Wang, Minwang Guo, Jingye Lu, Yan Li, Hongxuan Feng, Xuetao Fu, Rujuan Zhou, Shouru Xue
Summary: The study found that in patients with acute ischemic stroke, YKL-40 may be considered as a useful biomarker for predicting stroke-associated pneumonia. The optimal cutoff value of YKL-40 as a predictor of SAP was determined to be 206.4 ng/mL, with a sensitivity of 63.1% and a specificity of 82.0%.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Nutrition & Dietetics
Dan Yan, Qiqi Huang, Caijun Dai, Wenwei Ren, Siyan Chen
Summary: This study found that in patients with acute ischemic stroke (AIS), high LDH and low albumin levels were associated with an increased risk of stroke-associated pneumonia (SAP). The LDH to albumin ratio (LAR) may serve as a potential predictor for the incidence of SAP.
FRONTIERS IN NUTRITION
(2021)
Review
Clinical Neurology
Lisa R. R. Sun, John K. Lynch
Summary: While rare, stroke in infants and children is a significant cause of mortality and chronic morbidity in the pediatric population. Advances in neuroimaging and stroke care protocols have improved the ability to diagnose and determine the causes of stroke in children. Recent therapeutic developments allow for targeted stroke prevention in high-risk conditions, but important knowledge gaps remain.
Article
Pharmacology & Pharmacy
Miaomiao Zhou, Qiong Luo, Younian Xu
Summary: This study examines the effects of dexmedetomidine on stroke-associated pneumonia (SAP) and finds that it does not alleviate symptoms or reduce the extent of infarction. The mechanism linking decreased CD3(+) T cells and DEX's influence on SAP requires further investigation.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Huijun Chen, Minjie Xu, Yezhi Huang, Jincai He, Wenwei Ren
Summary: This study found that low T3 syndrome may be a risk factor for SAP in stroke patients. Patients with low T3 syndrome were more likely to develop SAP and had a higher risk of severe SAP.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Microbiology
Jie Zhao, Lei-qing Li, Ning-xin Zhen, Lin-lin Du, Hui Shan, Yang Yu, Zhao-cai Zhang, Wei Cui, Bao-ping Tian
Summary: This study found that 42.5% of patients developed SAP after stroke, with Gram-negative aerobic bacilli being the predominant organisms. SAP prolongs the duration of MV, ICU and hospital stays, and significantly increases 60-day mortality.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Clinical Neurology
Changling Li, Mengmeng Ma, Shuju Dong, Ye Hong, Jiajia Bao, Yang Zhang, Lijie Gao, Chaohua Cui, Jian Guo, Li He
Summary: The study found that there were no additional benefits of statin treatment in the acute phase for reducing post-stroke pneumonia among AIS patients. Statin treatment did not significantly increase the risk or severity of post-stroke pneumonia.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Marco Antonio Lobo Chaves, Matthew Gittins, Benjamin Bray, Andy Vail, Craig J. Smith
Summary: The study revealed that 8.5% of stroke patients developed stroke associated pneumonia. A longer time to arrival at a stroke unit, assessment by a stroke specialist, and assessment by a physiotherapist were all independently associated with a higher risk of stroke associated pneumonia. Shorter door to needle times were associated with lower odds of stroke associated pneumonia.
FRONTIERS IN NEUROLOGY
(2022)
Article
Cell Biology
Guomei Shi, Minghao Li, Rujuan Zhou, Xiaorong Wang, Wu Xu, Feng Yang, Shouru Xue
Summary: This study showed that higher serum procalcitonin levels were associated with an increased risk of stroke-associated pneumonia, poor clinical outcomes, and mortality in patients with acute ischemic stroke. Procalcitonin was found to be a reliable diagnostic and prognostic biomarker for stroke-associated pneumonia and poor outcomes in Chinese patients receiving intravenous rt-PA treatment.
CELLULAR AND MOLECULAR NEUROBIOLOGY
(2022)
Article
Engineering, Industrial
Guibing Gao, Dengming Zhou, Hao Tang, Xin Hu
Summary: The method utilizes the vulnerability of equipment to conduct health diagnosis strategies, assisting maintenance personnel in accurately diagnosing equipment health and promptly implementing maintenance plans.
RELIABILITY ENGINEERING & SYSTEM SAFETY
(2021)
Review
Clinical Neurology
Andreas Meisel, Fulvio Baggi, Anthony Behin, Amelia Evoli, Anna Kostera-Pruszczyk, Renato Mantegazza, Raul Juntas Morales, Anna Rostedt Punga, Sabrina Sacconi, Michael Schroeter, Jan Verschuuren, Louise Crathorne, Kris Holmes, Maria-Isabel Leite
Summary: This study examined the relationship between autoantibody levels and disease activity in patients with myasthenia gravis (MG). The results indicated a potential positive correlation, which could have clinical implications in guiding treatment decisions. However, due to limited and variable evidence, routine clinical use of autoantibody level testing is not currently recommended.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Frauke Stascheit, Ulrike Grittner, Sarah Hoffmann, Philipp Mergenthaler, Michael Schroeter, Tobias Ruck, Mark Pawlitzki, Franz Blaes, Julia Kaiser, Ulrike Schara, Adela Della-Marina, Andrea Thieme, Tim Hagenacker, Christian Jacobi, Benjamin Berger, Peter P. Urban, Karl Christian Knop, Berthold Schalke, De-Hyung Lee, Petra Kalischewski, Heinz Wiendl, Andreas Meisel
Summary: Current immunosuppressive therapy (IST) increases the severity of COVID-19 in patients with myasthenia gravis, but it does not increase the risk of SARS-CoV-2 infection. Therefore, effective strategies should be implemented to prevent COVID-19 in this high-risk group.
JOURNAL OF NEUROLOGY
(2023)
Letter
Clinical Neurology
Andreas Meisel, Fulvio Baggi, Anthony Behin, Amelia Evoli, Anna Kostera-Pruszczyk, Renato Mantegazza, Raul Juntas Morales, Anna Rostedt Punga, Sabrina Sacconi, Michael Schroeter, Jan Verschuuren, Louise Crathorne, Kris Holmes, Maria-Isabel Leite
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Letter
Clinical Neurology
Sarah Hoffmann, Werner Stenzel, Andreas Meisel
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Sarah Hoffmann, Patrick Waters, Leslie Jacobson, Markus Schuelke, Werner Stenzel, Tobias Ruck, Sophie Lehnerer, Frauke Stascheit, Corinna Preusse, Andreas Meisel
Summary: Autoantibody testing is essential for autoimmune myasthenia gravis diagnosis, but about 15% of patients still show negative results (seronegative MG). This study examined the prevalence of clustered AChR, MuSK, and LRP4 autoantibodies in a large German cohort of seronegative MG patients using a live cell-based assay. Out of 67 SNMG patients, 4.5% had clustered AChR autoantibodies, with two patients showing binding to both adult and fetal AChR. None of the patients tested positive for MuSK or LRP4 autoantibodies. Clinical characteristics were similar between patients with and without clustered AChR autoantibodies. Comparisons with a national MG registry showed broad similarities among seronegative MG patients in both cohorts.
NEUROMUSCULAR DISORDERS
(2023)
Article
Medicine, General & Internal
Sarah Dewilde, Glenn Philips, Sandra Paci, Jon Beauchamp, Silvia Chiroli, Casey Quinn, Laura Day, Mark Larkin, Jacqueline Palace, Sonia Berrih-Aknin, Kristl G. Claeys, Srikanth Muppidi, Renato Mantegazza, Francesco Sacca, Andreas Meisel, Guillaume Bassez, Hiroyuki Murai, M. F. Janssen
Summary: This study aims to explore the impact of myasthenia gravis (MG) on health-related quality of life (HRQoL) from the perspective of patients. The results showed that MG significantly affects patients' daily activities, anxiety and depression, fatigue, breathing, and vision. The impact of the disease becomes more severe with increasing disease severity.
Article
Clinical Neurology
Frauke Stascheit, Annette Aigner, Philipp Mergenthaler, Benjamin Hotter, Sarah Hoffmann, Sophie Lehnerer, Christian Meisel, Andreas Meisel
Summary: This study aimed to evaluate the association between Nfl and neuromuscular destruction and disease severity in MG patients. Serum samples from MG patients and controls were analyzed and compared. The results showed that sNfl levels were higher in MG patients compared to controls, but were not consistently associated with disease severity. Thus, sNfl is not a suitable biomarker for monitoring individual disease progression in MG patients.
FRONTIERS IN NEUROLOGY
(2023)
Article
Clinical Neurology
Frauke Stascheit, Omar Chuquisana, Christian W. Keller, Philip Alexander Ambrose, Sarah Hoffmann, Catharina C. Gross, Sophie Lehnerer, Heinz Wiendl, Nick Willcox, Andreas Meisel, Jan D. Luenemann
Summary: In patients with AChR-Ab(+) MG, there is significantly increased activation of the complement system, which remains present even under standard immunosuppressive therapies but is not evident in patients with MuSK-Abs or seronegative MG. Further exploration of complement inhibition proximal to C5 cleavage is suggested for potential therapeutic benefits in AChR-Ab(+) MG.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Antje Mevius, Lars Joeres, Jutta Biskup, Tanja Heidbrede, Milada Mahic, Thomas Wilke, Ulf Maywald, Sophie Lehnerer, Andreas Meisel
Summary: The aim of this retrospective cohort study was to estimate the prevalence and incidence of myasthenia gravis (MG) in Germany and understand the burden of disease and treatment patterns. The study found that the prevalence of MG in Germany was approximately 39.3/10 0,0 0 0, and the incidence in 2019 was 4.6/10 0,0 0 0. A significant proportion of MG patients remained untreated, and many patients experienced exacerbations or myasthenic crises. MG was associated with higher mortality compared to the general non-MG population.
NEUROMUSCULAR DISORDERS
(2023)
Article
Medicine, General & Internal
Sonia Berrih-Aknin, Jacqueline Palace, Andreas Meisel, Kristl G. Claeys, Srikanth Muppidi, Francesco Sacca, Fatemeh Amini, Mark Larkin, Casey Quinn, Jon Beauchamp, Glenn Philips, Femke De Ruyck, Joyce Ramirez, Sandra Paci
Summary: This study aims to explore the impact of myasthenia gravis (MG) in the real world from a patient perspective. The study included MG patients from different countries and found that despite current treatments, patients still experience a significant burden.
Article
Medicine, Research & Experimental
Christopher Nelke, Christina B. Schroeter, Frauke Stascheit, Niklas Huntemann, Marc Pawlitzki, Alice Willison, Saskia Raeuber, Nico Melzer, Ute Distler, Stefan Tenzer, Kai Stuehler, Andreas Roos, Andreas Meisel, Sven G. Meuth, Tobias Ruck
Summary: Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis. A combined proteomics and metabolomics approach was used to study a cohort of MG patients treated with eculizumab or azathioprine, as well as treatment-naive patients. Eculizumab was found to modulate the serum proteometabolome, affecting pathways related to oxidative stress, MAP kinase signaling, and lipid metabolism, particularly arachidonic acid signaling.
Article
Multidisciplinary Sciences
Kathrin Goedde, Hella Fuegemann, Ute Goerling, Ulrike Grittner, Raphael Kohl, Andreas Meisel, Thomas Reinhold, Susanne J. Schnitzer, P. Markus Deckert, Nikolaj Frost, Stephan Schreiber, Nina Rieckmann, Christine Holmberg
Summary: This feasibility study aims to evaluate a patient-oriented navigation model that integrates data about barriers to care, vulnerable patient populations, and existing support services. The study consists of two randomized controlled trials and observational cohorts, with the intervention group receiving support from personal navigators for 12 months while the control group receives a brochure with regional support offers. The feasibility of the navigation model is evaluated in terms of acceptance, demand, practicality, and efficacy.
Article
Public, Environmental & Occupational Health
Hannes Wartmann, Sarah Hoffmann, Tobias Ruck, Christopher Nelke, Barthold Deiters, Timm Volmer
Summary: This is a study on the prevalence and incidence rates of myasthenia gravis (MG) in Germany. The study found that the prevalence rate of MG increased by 1.8-fold over the past 10 years, while the incidence rate decreased significantly in 2020 due to the impact of the COVID-19 pandemic. Treatment patterns are also changing, with an increasing use of therapeutic monoclonal antibodies.
